Compare Johnson & Johnson (JNJ) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

PALL (abrdn Physical Palladium Shares ETF) trades at $22.80, up 0.44% with a bearish technical signal from moving averages. Recent news highlights palladium's underperformance versus other precious metals, though some analysts see current price weakness as a buying opportunity. The ETF underwent a 5-for-1 forward share split on May 18, 2026, which adjusted share count without changing the underlying value.

The outlook for PALL hinges on palladium's supply-demand dynamics and industrial usage. While technical indicators suggest near-term pressure, fundamental factors like supply constraints and potential demand recovery could support prices. Key risks include Federal Reserve policy impacts and global economic conditions affecting industrial demand for palladium.